New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
17:35 EDTBEAM, AIV, PG, HME, PAH, GGP, AGNPershing Square gives quarterly update on stakes
NEW STAKES: Platform Specialty Products (PAH), Apartment Investment and Management (AIV), Allergan (AGN), and Home Properties (HME). INCREASED STAKES: None. DECREASED STAKES: Beam (BEAM). LIQUIDATED STAKES: General Growth Properties (GGP), and Procter & Gamble (PG).
News For PAH;AIV;AGN;HME;BEAM;GGP;PG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
08:04 EDTAGNAllergan completes Nuarex acquisition
Subscribe for More Information
07:39 EDTAGNCiti calls Allergan a 'stock to own,' keeps $360 target
Citi analyst Liav Abraham calls Allergan a "stock to own" given its "attractive" organic growth profile, pipeline potential and ability to do more acquisitions. He reiterates a Buy rating on the stock with a $360 price target.
07:24 EDTPAHPlatform Specialty Products receives early termination of HSR Act waiting period
Platform Specialty Products said in a regulatory filing that on August 28, the company announced that it had received notice of the early termination of the antitrust waiting period under the Hart-Scott Rodino Antitrust Improvements Act in connection with its recommended offer to acquire all of the issued and to be issued shares of Alent plc by MacDermid Performance Acquisitions Ltd, a wholly owned indirect subsidiary of Platform, by way of a court-sanctioned scheme of arrangement under the U.K. Companies Act 2006. The early termination of the HSR Act waiting period satisfies a condition to the Scheme. The Scheme remains subject to certain other conditions and approvals, including, among others, Alent shareholder approval and regulatory approvals in certain other jurisdictions.
August 30, 2015
12:33 EDTPGDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 28, 2015
09:50 EDTAGNAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.
06:28 EDTPAHPlatform Specialty, Alent receive US antitrust clearance for deal, Reuters says
Subscribe for More Information
August 27, 2015
09:27 EDTPAHPlatform Specialty Products announces common stock purchase by founders
Platform Specialty Products announces the recent purchase of an aggregate of 448,200 shares of Platform's common stock by its chairman and by the Nicolas Berggruen Charitable Foundation. Martin Franklin, Platform's chairman, filed a Form 4 with the SEC announcing the purchase of an aggregate of 224,100 shares of Platform's common stock in the open market. In addition, on August 25 and 26, the Foundation purchased an aggregate of 224,100 shares of Platform's common stock in the open market. Nicolas Berggruen, a director of Platform, is the president of the Foundation and one of the directors of Berggruen Holdings.
August 26, 2015
08:03 EDTGGPGeneral Growth increases share repurchase program by $500M
Subscribe for More Information
August 25, 2015
08:47 EDTPGKellogg names Carolyn Tastad to board of directors
Subscribe for More Information
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
August 24, 2015
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
August 20, 2015
10:00 EDTGGPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
06:34 EDTGGPGeneral Growth upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use